5-methoxy-N,N-dimethyltryptamine-oxide | 4006-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-methoxy-N,N-dimethyltryptamine-oxide
• 英文别名: 5-Methoxy-N(ω),N(ω)-dimethyl-tryptamin-N(ω)-oxid；5-Methoxy-N,N-dimethyl-tryptamin-oxid；5-Hydroxy-N,N-dimethyl-tryptamin-N(b)-oxid；5-Methoxy-N,N-dimethyl-tryptamin-N-oxid；[2-(5-methoxy-indol-3-yl)-ethyl]-dimethyl-amine oxide；2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine oxide
• CAS: 4006-02-4
• 化学式: C₁₃H₁₈N₂O₂
• 分子量: 234.298
• InChiKey: AVIICGUHIIDHRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Pharmaceutical compositions and uses comprising mucuna pruriens seed powder and extracts thereof in the treatment of neurological diseases
  申请人：Van Der Giessen Rob

  公开号：US20060165822A1

  公开（公告）日：2006-07-27

  The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases. Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.

  本发明提供的药物组合物包含 金丝桃 种子或一种或多种 种子成分、物质、馏分或混合物 种子成分、物质、馏分或混合物或从中获得的物质。此外，本发明还涉及使用 白桑子 种子粉末或一种或多种 成分、物质、馏分或混合物的用途。 成分、物质、馏分或混合物或从中获得的物质，用于制备预防、缓解或治疗神经系统疾病的药物组合物。此外，本发明还涉及使用 种子 种子用于制备神经保护或神经刺激的药物组合物，以及制备以下提取物的方法 的提取物的制备方法。 的提取物的制备方法，这些提取物可用于制备治疗神经系统疾病的药物组合物。最后，本发明涉及使用 种子 种子用于制备治疗帕金森病的药物组合物，以获得更广泛的左旋多巴治疗窗口，延迟联合治疗的需要，获得更早的左旋多巴疗效和更长的疗效持续时间，以及预防或减轻急性和慢性左旋多巴毒性。
• MUCUNA PRURIENS AND EXTRACTS THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES
  申请人：Phytrix AG

  公开号：EP1567177B1

  公开（公告）日：2008-04-23
• US7470441B2
  申请人：——

  公开号：US7470441B2

  公开（公告）日：2008-12-30
• [EN] PHARMACEUTICAL COMPOSITIONS AND USES COMPRISING MUCUNA PRURIENS SEED POWDER AND EXTRACTS THEREOF IN THE TREATMENT OF NEUROLOGICAL DISEASES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DE LA POUDRE DE GRAINES DE MUCUNA PRURIENS ET DES EXTRAITS DE CELUI-CI ET UTILISATIONS DANS LE TRAITEMENT DE MALADIES NEUROLOGIQUES
  申请人：PHYTRIX AG

  公开号：WO2004039385A2

  公开（公告）日：2004-05-13

  The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases. Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.